← Back to events
ActiveBusiness

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Photo: MarketWatch

What happened

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.

Summary assembled by rule from the sources below

Sources